Medtronic (NYSE: MDT) announced that the U.S. Food and Drug Administration has cleared the LigaSure RAS Maryland jaw device for use with the company's Hugo robotic-assisted surgery (RAS) system.

The instrument is designed exclusively for use with the Valleylab FT10 energy platform on the Hugo RAS system. It seals and cuts vessels, thick tissue, and lymphatics up to 7 mm in diameter, completing vessel seals in approximately two seconds. Medtronic states the device minimizes thermal spread to surrounding tissue.

According to the company, LigaSure technology has been used in more than 45 million procedures across more than 65 countries over the past two decades. The LigaSure RAS Maryland instrument was previously introduced on the Hugo RAS system in Europe in 2025 following CE Mark approval.

The Hugo RAS system is currently cleared in the U.S. for urologic surgical procedures. Medtronic said it is continuing to pursue expanded indications for the system, including general and gynecologic surgical procedures in the U.S. Outside the U.S., the system is used across more than 35 countries in more than 50 surgical procedures.

"Vessel sealing sits at the center of how surgeons work through the most demanding moments of a procedure, and surgeons have trusted LigaSure to do it across open and laparoscopic surgery for decades," said Dr. Matthew Kroh, chief medical officer within the Surgical business at Medtronic and a practicing surgeon. "Bringing that same performance to the Hugo RAS system in the U.S. means surgeons carry the confidence and control they already rely on into their robotic-assisted cases."

Medtronic is headquartered in Galway, Ireland, and employs more than 95,000 people across more than 150 countries.